{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:41:50Z","timestamp":1791283310119,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cardiacep.theclinics.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiac Electrophysiology Clinics"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.ccep.2016.02.007","type":"journal-article","created":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T05:33:11Z","timestamp":1464759191000},"page":"437-452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Sotalol"],"prefix":"10.1016","volume":"8","author":[{"suffix":"Jr.","given":"John Alvin","family":"Kpaeyeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Marcus","family":"Wharton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccep.2016.02.007_bib1","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/2031283a0","article-title":"A\u00a0new bio-isostere: alkylsulphonamidophenethanolamines","volume":"203","author":"Larsen","year":"1964","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ccep.2016.02.007_bib2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0735-1097(86)80268-6","article-title":"Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in\u00a0vivo pharmacokinetics","volume":"7","author":"Kato","year":"1986","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ccep.2016.02.007_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1085\/jgp.96.1.195","article-title":"Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents","volume":"96","author":"Sanguinetti","year":"1990","journal-title":"J\u00a0Gen Physiol"},{"issue":"2","key":"10.1016\/j.ccep.2016.02.007_bib4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00005344-199302000-00019","article-title":"Action potential prolongation exhibits simple dose-dependence for sotalol, but reverse dose-dependence for quinidine and disopyramide: implications for proarrhythmia due to triggered activity","volume":"21","author":"Wyse","year":"1993","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"3","key":"10.1016\/j.ccep.2016.02.007_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000316050","article-title":"QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol","volume":"116","author":"Somberg","year":"2010","journal-title":"Cardiology"},{"issue":"3","key":"10.1016\/j.ccep.2016.02.007_bib6","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/bcp.12201","article-title":"Are women more susceptible than men to drug-induced QT prolongation? concentration-QTc modelling in a phase 1 study with oral rac-sotalol","volume":"77","author":"Darpo","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.ccep.2016.02.007_bib7","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/0002-9149(91)90191-M","article-title":"Reverse use-dependent effects of sotalol demonstrated by recording monophasic action potentials of the right ventricle","volume":"68","author":"Schmitt","year":"1991","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.ccep.2016.02.007_bib8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1023\/A:1007743521932","article-title":"Differential rate and potassium-dependent effects of the class III agents d-sotalol and dofetilide on guinea pig papillary muscle","volume":"12","author":"Marschang","year":"1998","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"10.1016\/j.ccep.2016.02.007_bib9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1540-8167.1997.tb00813.x","article-title":"Insights into mechanisms of antiarrhythmic drug action from experimental models of atrial fibrillation","volume":"8","author":"Nattel","year":"1997","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"issue":"6","key":"10.1016\/j.ccep.2016.02.007_bib10","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1136\/hrt.79.6.568","article-title":"Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The ibutilide\/sotalol comparator study group","volume":"79","author":"Vos","year":"1998","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.ccep.2016.02.007_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cardiores.2005.02.019","article-title":"Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs","volume":"67","author":"Duytschaever","year":"2005","journal-title":"Cardiovasc Res"},{"issue":"12","key":"10.1016\/j.ccep.2016.02.007_bib12","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/S0735-1097(02)02592-5","article-title":"Electrophysiologic actions of dl-sotalol in patients with persistent atrial fibrillation","volume":"40","author":"Tse","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.ccep.2016.02.007_bib13","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1096\/fj.02-1057fje","article-title":"The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines","volume":"17","author":"Kupershmidt","year":"2003","journal-title":"FASEB J"},{"issue":"3","key":"10.1016\/j.ccep.2016.02.007_bib14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.113.007765","article-title":"Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current","volume":"130","author":"Yang","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ccep.2016.02.007_bib15","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1476-5381.2010.01181.x","article-title":"Modulation of the late sodium current by ATX-II and ranolazine affects the reverse use-dependence and proarrhythmic liability of IKr blockade","volume":"164","author":"Jia","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.ccep.2016.02.007_bib16","first-page":"1095","article-title":"Effects on atrial repolarization of the interaction between K+ channel blockers and muscarinic receptor stimulation","volume":"273","author":"Zaza","year":"1995","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.ccep.2016.02.007_bib17","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1161\/01.CIR.91.11.2834","article-title":"Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells. Different molecular mechanisms","volume":"91","author":"Mori","year":"1995","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccep.2016.02.007_bib18","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/01.CIR.90.4.2032","article-title":"Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide","volume":"90","author":"Wang","year":"1994","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ccep.2016.02.007_bib19","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.hrthm.2011.07.018","article-title":"Combined blockade of early and late activated atrial potassium currents suppresses atrial fibrillation in a pig model of obstructive apnea","volume":"8","author":"Linz","year":"2011","journal-title":"Heart Rhythm"},{"issue":"2\u20133","key":"10.1016\/j.ccep.2016.02.007_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0014-2999(86)90597-2","article-title":"Comparative beta-blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anesthetized dogs","volume":"132","author":"Gomoll","year":"1986","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.ccep.2016.02.007_bib21","doi-asserted-by":"crossref","first-page":"19A","DOI":"10.1016\/0002-9149(93)90021-4","article-title":"Clinical pharmacokinetics of sotalol","volume":"72","author":"Hanyok","year":"1993","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.ccep.2016.02.007_bib22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1161\/01.CIR.91.2.262","article-title":"Beta-adrenergic blocking property of dl-sotalol maintains class III efficacy in guinea pig ventricular muscle after isoproterenol","volume":"91","author":"Groh","year":"1995","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ccep.2016.02.007_bib23","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1046\/j.1540-8167.2003.02413.x","article-title":"Beta receptor blockade potentiates the antiarrhythmic actions of d-sotalol on reentrant ventricular tachycardia in a canine model of myocardial infarction","volume":"14","author":"Kassotis","year":"2003","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"issue":"3","key":"10.1016\/j.ccep.2016.02.007_bib24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.hrthm.2011.10.021","article-title":"Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations","volume":"9","author":"Sicouri","year":"2012","journal-title":"Heart Rhythm"},{"issue":"2","key":"10.1016\/j.ccep.2016.02.007_bib25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2125.1990.tb03765.x","article-title":"A\u00a0mechanism of D-(+)-sotalol effects on heart rate not related to beta-adrenoceptor antagonism","volume":"30","author":"Funck-Brentano","year":"1990","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.ccep.2016.02.007_bib26","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/clpt.1993.48","article-title":"D-sotalol reduces heart rate in\u00a0vivo through a beta-adrenergic receptor-independent mechanism","volume":"53","author":"Yasuda","year":"1993","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ccep.2016.02.007_bib27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1254\/jphs.08312FP","article-title":"Effects of antiarrhythmic drugs on the hyperpolarization-activated cyclic nucleotide-gated channel current","volume":"110","author":"Tamura","year":"2009","journal-title":"J\u00a0Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.ccep.2016.02.007_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MJT.0b013e3181ea3184","article-title":"Developing a safe intravenous sotalol dosing regimen","volume":"17","author":"Somberg","year":"2010","journal-title":"Am J Ther"},{"issue":"1","key":"10.1016\/j.ccep.2016.02.007_bib29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/1074248411406505","article-title":"Gender differences in cardiac repolarization following intravenous sotalol administration","volume":"17","author":"Somberg","year":"2012","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ccep.2016.02.007_bib30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/clpt.1981.63","article-title":"Sotalol kinetics in renal insufficiency","volume":"29","author":"Blair","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ccep.2016.02.007_bib31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2125.1976.tb00601.x","article-title":"The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol","volume":"3","author":"Tjandramaga","year":"1976","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.ccep.2016.02.007_bib32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/BF00609896","article-title":"Pharmacokinetics of sotalol during pregnancy","volume":"24","author":"O'Hare","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.ccep.2016.02.007_bib33","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1471-0528.1980.tb04618.x","article-title":"Sotalol as a hypotensive agent in pregnancy","volume":"87","author":"O'Hare","year":"1980","journal-title":"Br J Obstet Gynaecol"},{"issue":"4","key":"10.1016\/j.ccep.2016.02.007_bib34","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1476-5381.1970.tb09893.x","article-title":"A\u00a0third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474","volume":"39","author":"Singh","year":"1970","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.ccep.2016.02.007_bib35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1527-3466.2001.tb00062.x","article-title":"Sotalol: the mechanism of its antiarrhythmic-defibrillating effect","volume":"19","author":"Manoach","year":"2001","journal-title":"Cardiovasc Drug Rev"},{"issue":"1","key":"10.1016\/j.ccep.2016.02.007_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJM199407073310108","article-title":"Sotalol","volume":"331","author":"Hohnloser","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ccep.2016.02.007_bib37","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1161\/01.CIR.94.10.2535","article-title":"Sex difference in risk of torsade de pointes with d,l-sotalol","volume":"94","author":"Lehmann","year":"1996","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccep.2016.02.007_bib38","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0002-9149(98)00868-6","article-title":"JTc prolongation with d,l-sotalol in women versus men","volume":"83","author":"Lehmann","year":"1999","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.ccep.2016.02.007_bib39","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/jama.285.10.1322","article-title":"Drug-induced QT prolongation in women during the menstrual cycle","volume":"285","author":"Rodriguez","year":"2001","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ccep.2016.02.007_bib40","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jacc.2005.06.061","article-title":"Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia","volume":"46","author":"Laer","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ccep.2016.02.007_bib41","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/hrt.47.6.515","article-title":"Electrophysiological effects of sotalol\u2013just another beta blocker?","volume":"47","author":"Nathan","year":"1982","journal-title":"Br Heart J"},{"issue":"3","key":"10.1016\/j.ccep.2016.02.007_bib42","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2125.1997.00506.x","article-title":"Interaction between sotalol and an antacid preparation","volume":"43","author":"Laer","year":"1997","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ccep.2016.02.007_bib43","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/01.CIR.76.2.324","article-title":"The hemodynamic effects of sotalol and quinidine: analysis by use of rest and exercise gated radionuclide angiography","volume":"76","author":"Mahmarian","year":"1987","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ccep.2016.02.007_bib44","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/oxfordjournals.eurheartj.a059552","article-title":"Multicentre randomized trial of sotalol vs amiodarone for chronic malignant ventricular tachyarrhythmias. Amiodarone vs sotalol study group","volume":"10","year":"1989","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ccep.2016.02.007_bib45","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1161\/01.CIR.72.3.555","article-title":"Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias","volume":"72","author":"Nademanee","year":"1985","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccep.2016.02.007_bib46","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0735-1097(86)80414-4","article-title":"Multicenter trial of sotalol for suppression of frequent, complex ventricular arrhythmias: a double-blind, randomized, placebo-controlled evaluation of two doses","volume":"8","author":"Anderson","year":"1986","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.ccep.2016.02.007_bib47","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1161\/01.CIR.92.10.2904","article-title":"Positive and negative inotropic effects of DL-sotalol and D-sotalol in failing and nonfailing human myocardium under physiological experimental conditions","volume":"92","author":"Holubarsch","year":"1995","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ccep.2016.02.007_bib48","first-page":"1276","article-title":"Risk of proarrhythmic events in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study: a multivariate analysis","volume":"44","author":"Kaufman","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.ccep.2016.02.007_bib49","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1540-8159.2006.00526.x","article-title":"Comparison of a standard versus accelerated dosing regimen for D,L-sotalol for the treatment of atrial and ventricular dysrhythmias","volume":"29","author":"Kim","year":"2006","journal-title":"Pacing Clin Electrophysiol"},{"issue":"1","key":"10.1016\/j.ccep.2016.02.007_bib50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0009-9236(99)70058-5","article-title":"Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects","volume":"66","author":"Barbey","year":"1999","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.ccep.2016.02.007_bib51","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/europace\/eut153","article-title":"QT variability during initial exposure to sotalol: experience based on a large electronic medical record","volume":"15","author":"Weeke","year":"2013","journal-title":"Europace"},{"issue":"1","key":"10.1016\/j.ccep.2016.02.007_bib52","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0735-1097(98)00189-2","article-title":"Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications","volume":"32","author":"Chung","year":"1998","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ccep.2016.02.007_bib53","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/pace.12586","article-title":"Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation","volume":"38","author":"Agusala","year":"2015","journal-title":"Pacing Clin Electrophysiol"},{"issue":"1","key":"10.1016\/j.ccep.2016.02.007_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00001573-200001000-00002","article-title":"Inpatient versus outpatient antiarrhythmic drug initiation: safety and cost-effectiveness issues","volume":"15","author":"Reiffel","year":"2000","journal-title":"Curr Opin Cardiol"},{"issue":"2","key":"10.1016\/j.ccep.2016.02.007_bib55","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1540-8167.2008.01318.x","article-title":"Effects of intrapericardial sotalol and flecainide on transmural atrial electrophysiology and atrial fibrillation","volume":"20","author":"van Brakel","year":"2009","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"issue":"6","key":"10.1016\/j.ccep.2016.02.007_bib56","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0002-9149(91)90013-B","article-title":"Usefulness of d, I sotalol for suppression of chronic ventricular arrhythmias","volume":"67","author":"Anastasiou-Nana","year":"1991","journal-title":"Am J Cardiol"},{"issue":"5 Pt 1","key":"10.1016\/j.ccep.2016.02.007_bib57","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/0002-8703(85)90237-6","article-title":"Comparative efficacy of oral sotalol and procainamide in patients with chronic ventricular arrhythmias: a multicenter study","volume":"109","author":"Lidell","year":"1985","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.ccep.2016.02.007_bib58","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJM198908103210629","article-title":"Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The cardiac arrhythmia suppression trial (CAST) investigators","volume":"321","year":"1989","journal-title":"N\u00a0Engl J Med"},{"issue":"8282","key":"10.1016\/j.ccep.2016.02.007_bib59","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(82)92225-5","article-title":"Controlled trial of sotalol for one year after myocardial infarction","volume":"1","author":"Julian","year":"1982","journal-title":"Lancet"},{"issue":"9019","key":"10.1016\/j.ccep.2016.02.007_bib60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(96)02149-6","article-title":"Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol","volume":"348","author":"Waldo","year":"1996","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ccep.2016.02.007_bib61","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/emermed-2013-202973","article-title":"Antidysrhythmic drug therapy for the termination of stable, monomorphic ventricular tachycardia: a systematic review","volume":"32","author":"deSouza","year":"2015","journal-title":"Emerg Med J"},{"issue":"8914","key":"10.1016\/j.ccep.2016.02.007_bib62","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0140-6736(94)91048-0","article-title":"Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia","volume":"344","author":"Ho","year":"1994","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ccep.2016.02.007_bib63","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1445-5994.2005.00896.x","article-title":"Randomized double-blind trial of sotalol versus lignocaine in out-of-hospital refractory cardiac arrest due to ventricular tachyarrhythmia","volume":"35","author":"Kovoor","year":"2005","journal-title":"Intern Med J"},{"issue":"1","key":"10.1016\/j.ccep.2016.02.007_bib64","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0735-1097(98)00521-X","article-title":"Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment","volume":"33","author":"Kuhlkamp","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ccep.2016.02.007_bib65","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0735-1097(97)00190-3","article-title":"Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest","volume":"30","author":"Haverkamp","year":"1997","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ccep.2016.02.007_bib66","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00005344-199510000-00019","article-title":"Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia","volume":"26","author":"Antz","year":"1995","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"7","key":"10.1016\/j.ccep.2016.02.007_bib67","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM199308123290702","article-title":"A\u00a0comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic study versus electrocardiographic monitoring investigators","volume":"329","author":"Mason","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ccep.2016.02.007_bib68","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/0002-9149(94)90463-4","article-title":"Electrophysiologic effects of sotalol and amiodarone in patients with sustained monomorphic ventricular tachycardia","volume":"74","author":"Man","year":"1994","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.ccep.2016.02.007_bib69","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0002-9149(97)00045-3","article-title":"Sotalol for ventricular tachyarrhythmias: beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. ESVEM investigators. Electrophysiologic study versus electrocardiographic monitoring","volume":"79","author":"Reiffel","year":"1997","journal-title":"Am J Cardiol"},{"issue":"18","key":"10.1016\/j.ccep.2016.02.007_bib70","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJMoa041705","article-title":"Amiodarone versus sotalol for atrial fibrillation","volume":"352","author":"Singh","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ccep.2016.02.007_bib71","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.7326\/0003-4819-139-12-200312160-00012","article-title":"Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography","volume":"139","author":"McNamara","year":"2003","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.ccep.2016.02.007_bib72","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S0002-9149(98)00223-9","article-title":"Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation","volume":"81","author":"Reisinger","year":"1998","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.ccep.2016.02.007_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mem.2000.107655","article-title":"A\u00a0prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation","volume":"36","author":"Joseph","year":"2000","journal-title":"Ann Emerg Med"},{"issue":"3","key":"10.1016\/j.ccep.2016.02.007_bib74","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0002-9149(99)00275-1","article-title":"Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and\/or atrial flutter. d,l-sotalol atrial fibrillation\/flutter study group","volume":"84","author":"Benditt","year":"1999","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.ccep.2016.02.007_bib75","doi-asserted-by":"crossref","first-page":"373.e1","DOI":"10.1016\/j.ahj.2008.01.032","article-title":"The drug and pace health cliNical evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker","volume":"156","author":"Capucci","year":"2008","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.ccep.2016.02.007_bib76","first-page":"51","article-title":"A\u00a0comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation","volume":"25","author":"Carunchio","year":"1995","journal-title":"G\u00a0Ital Cardiol"},{"issue":"7","key":"10.1016\/j.ccep.2016.02.007_bib77","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0002-9149(93)90511-A","article-title":"Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation","volume":"71","author":"Reimold","year":"1993","journal-title":"Am J Cardiol"},{"issue":"11 Pt 2","key":"10.1016\/j.ccep.2016.02.007_bib78","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/j.1540-8159.2000.tb07044.x","article-title":"Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?","volume":"23","author":"Kochiadakis","year":"2000","journal-title":"Pacing Clin Electrophysiol"},{"issue":"16","key":"10.1016\/j.ccep.2016.02.007_bib79","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.ehj.2004.06.014","article-title":"Suppression of paroxysmal atrial tachyarrhythmias\u2013results of the SOPAT trial","volume":"25","author":"Patten","year":"2004","journal-title":"Eur Heart J"},{"issue":"13","key":"10.1016\/j.ccep.2016.02.007_bib80","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM200003303421302","article-title":"Amiodarone to prevent recurrence of atrial fibrillation. Canadian trial of atrial fibrillation investigators","volume":"342","author":"Roy","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ccep.2016.02.007_bib81","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ahj.2006.12.020","article-title":"Exercise capacity in atrial fibrillation: a substudy of the sotalol-amiodarone atrial fibrillation efficacy trial (SAFE-T)","volume":"153","author":"Atwood","year":"2007","journal-title":"Am Heart J"},{"issue":"19","key":"10.1016\/j.ccep.2016.02.007_bib82","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.jacc.2011.07.036","article-title":"Cardiovascular outcomes in the AFFIRM trial (atrial fibrillation follow-up investigation of rhythm management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses","volume":"58","author":"Saksena","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.ccep.2016.02.007_bib83","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/europace\/eup119","article-title":"Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study","volume":"11","author":"Andersen","year":"2009","journal-title":"Europace"},{"issue":"2","key":"10.1016\/j.ccep.2016.02.007_bib84","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0735-1097(99)00213-2","article-title":"Oral d,l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study","volume":"34","author":"Gomes","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ccep.2016.02.007_bib85","doi-asserted-by":"crossref","first-page":"875.e1","DOI":"10.1016\/j.amjmed.2011.04.025","article-title":"The efficacy of sotalol in preventing postoperative atrial fibrillation: a meta-analysis","volume":"124","author":"Kerin","year":"2011","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.ccep.2016.02.007_bib86","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005344-199801000-00010","article-title":"Comparison of sotalol and metoprolol in the prevention of atrial fibrillation after coronary artery bypass surgery","volume":"31","author":"Parikka","year":"1998","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.ccep.2016.02.007_bib87","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1749-8090-1-6","article-title":"Does prophylactic sotalol and magnesium decrease the incidence of atrial fibrillation following coronary artery bypass surgery: a propensity-matched analysis","volume":"1","author":"Aerra","year":"2006","journal-title":"J\u00a0Cardiothorac Surg"},{"issue":"2","key":"10.1016\/j.ccep.2016.02.007_bib88","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1510\/icvts.2004.102152","article-title":"Is sotalol more effective than standard beta-blockers for the prophylaxis of atrial fibrillation during cardiac surgery","volume":"4","author":"Patel","year":"2005","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"1","key":"10.1016\/j.ccep.2016.02.007_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003611.pub3","article-title":"Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery","author":"Arsenault","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ccep.2016.02.007_bib90","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0002-9149(91)90706-Q","article-title":"Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia. The sotalol versus placebo multicenter study group","volume":"68","author":"Jordaens","year":"1991","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.ccep.2016.02.007_bib91","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/0002-9149(92)90993-9","article-title":"Efficacy of intravenous sotalol for suppressing inducibility of supraventricular tachycardias at rest and during isometric exercise","volume":"69","author":"Huikuri","year":"1992","journal-title":"Am J Cardiol"},{"issue":"7 Pt 1","key":"10.1016\/j.ccep.2016.02.007_bib92","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1111\/j.1540-8159.1993.tb01734.x","article-title":"Oral flecainide, sotalol, and verapamil for the termination of paroxysmal supraventricular tachycardia","volume":"16","author":"Hamer","year":"1993","journal-title":"Pacing Clin Electrophysiol"},{"issue":"9","key":"10.1016\/j.ccep.2016.02.007_bib93","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.amjcard.2013.07.029","article-title":"Efficacy of antiarrhythmic drugs in adults with congenital heart disease and supraventricular tachycardias","volume":"112","author":"Koyak","year":"2013","journal-title":"Am J Cardiol"},{"issue":"16","key":"10.1016\/j.ccep.2016.02.007_bib94","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1161\/CIRCULATIONAHA.111.026120","article-title":"Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study","volume":"124","author":"Jaeggi","year":"2011","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ccep.2016.02.007_bib95","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.amjcard.2012.01.388","article-title":"Effectiveness of sotalol as first-line therapy for fetal supraventricular tachyarrhythmias","volume":"109","author":"Shah","year":"2012","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.ccep.2016.02.007_bib96","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/uog.12390","article-title":"Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up","volume":"42","author":"van der Heijden","year":"2013","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ccep.2016.02.007_bib97","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-5273(99)00055-8","article-title":"Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment","volume":"69","author":"Kuhlkamp","year":"1999","journal-title":"Int J Cardiol"},{"issue":"1 Pt 1","key":"10.1016\/j.ccep.2016.02.007_bib98","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0002-8703(96)90398-1","article-title":"Effect of parenteral d-sotalol on transvenous atrial defibrillation threshold in a canine model of atrial fibrillation","volume":"132","author":"Iskos","year":"1996","journal-title":"Am Heart J"},{"issue":"10 Pt 1","key":"10.1016\/j.ccep.2016.02.007_bib99","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1111\/j.1540-8159.1997.tb06084.x","article-title":"A\u00a0comparison of transvenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold","volume":"20","author":"Lau","year":"1997","journal-title":"Pacing Clin Electrophysiol"},{"issue":"2","key":"10.1016\/j.ccep.2016.02.007_bib100","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1161\/CIRCULATIONAHA.106.618421","article-title":"Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial","volume":"114","author":"Hohnloser","year":"2006","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ccep.2016.02.007_bib101","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1540-8167.1996.tb00469.x","article-title":"D-sotalol decreases defibrillation energy requirements in humans: a novel indication for drug therapy","volume":"7","author":"Dorian","year":"1996","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"issue":"6","key":"10.1016\/j.ccep.2016.02.007_bib102","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0002-9149(98)00478-0","article-title":"Comparison of\u00a0metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter\/defibrillator","volume":"82","author":"Seidl","year":"1998","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.ccep.2016.02.007_bib103","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.295.2.165","article-title":"Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from\u00a0implantable cardioverter defibrillators: the OPTIC study: a randomized trial","volume":"295","author":"Connolly","year":"2006","journal-title":"JAMA"}],"container-title":["Cardiac Electrophysiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877918216300144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877918216300144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T22:35:58Z","timestamp":1656628558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877918216300144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1877918216300144"],"URL":"https:\/\/doi.org\/10.1016\/j.ccep.2016.02.007","relation":{},"ISSN":["1877-9182"],"issn-type":[{"value":"1877-9182","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sotalol","name":"articletitle","label":"Article Title"},{"value":"Cardiac Electrophysiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccep.2016.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}